NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today…#gaithersburg #neximmune #hcwainwrightco #forms3 #llc #430parkavenue #3rdfloor #section4a2 #securitiesact #aim
Source: Reuters: Health - Category: Consumer Health News Source Type: news